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Discussion
Dr Gerald D. Buckberg (Los Angeles, Calif). I would like to
compliment Dr Bolooki for an important review of the geometric
changes after anterior infarction that link the evolution of correc-
tive measures with early and late results. Improvement followed
changing from a linear resection to include the septum, to plicating
the dyskinetic septum with a triangular patch as described in 1986,
to more recently excluding the septum with an oval patch to restore
an elliptical shape. The composite results may lead to some con-
fusion because different reasons can explain why high-risk com-
ponents of EF, pulmonary artery pressure, and the need for a
balloon will raise mortality. From a mechanical standpoint, patch
exclusion of the septum is a more complete procedure and was
more successful in his presentation, despite the occurrence of the
lowest EF of 22% and highest PA pressure of 21 mm Hg. Fur-
thermore, adding patients with cardiogenic shock raises early
mortality. Is their analysis without this data available?
Dr Bolooki. Yes. The article has more detailed data analysis.
You are correct, patients with an intraventricular patch had overall
higher survival results.
The composite slide (Figure 6) showed that by excluding the
operative mortality, there is approximately a 10% better survivor-
ship at 5 years, 7% at 10 years, and 4% at 15 years for the 3 patient
groups. There were no statistically significant differences in over-
all survival among the 3 groups at 5 years. However, at 7 years of
follow-up, the difference in survival was better for group III (patch
exclusion of the septum) than for group II (septal inclusion).
Preoperative use of a balloon pump, cardiogenic shock, and emer-
gency operations had a significant effect on operative (in-hospital
death) survival, but only balloon-pump use had an effect on
long-term survival curves.
Dr Buckberg. I think that is correct, because a clearer picture
emerges when you look at elective high-risk patients. We recently
analyzed 662 patients, mostly in class III or IV heart failure, and
the balloon was only needed in approximately 8%. Hospital mor-
tality for restoration without repair was approximately 4%, so that
goes along with what you are saying. I think that separating
elective versus urgent operations will reduce the mortality as you
describe, and you demonstrate that in your slide.
It seems that the consideration of methods of protection may
suggest that the beating empty heart, rather than cardioplegia, may
be useful for restoration when there is trabecular scar. This is
because aneurysms are fairly rare today with the use of thrombol-
ysis and percutaneous transluminal coronary angioplasty. How-
ever, the akinetic heart is relatively common. The thick akinetic
heart is seen by echocardiography and ventriculography, and it
does not collapse by venting. The junction between contracting
and noncontracting muscle is found by palpation. I wonder how
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many thick akinetic hearts you see, because they are what we see
most commonly.
Dr Bolooki. This operation involved infarcted, mostly dyski-
netic anterior LV segments. I agree that the hearts with enlarged
LV with an akinetic trabeculated anterior wall are a surgical
challenge. This is because of the absence of a clear demarcation
line to identify the contractile from the noncontractile parts. Finger
palpation of the wall in a beating open LV cavity will help in
delineating the contracting parts, but we have always believed that
myocardial contraction, in thick-walled hibernating areas of the
LV, may return after they are revascularized.
Dr Buckberg. Thickness is what I am getting at.
Dr Bolooki. Many of the patients who have a thick akinetic
anterior wall LV do have coronary artery disease. At the present
time, we perform coronary bypass operation in these patients and
do not rely on volume reduction surgery. This trend may change as
time goes on, and we may perform volume reduction surgery and
myocardial revascularization concomitantly in patients with a
thick wall akinetic myocardium.
Dr Buckberg. You basically have not operated on the akinetic
thick ventricles. You mainly revascularize those.
Dr Bolooki. That is correct. If there is obstructive disease
coronary disease, we perform a coronary bypass operation and do
not reduce the LV volume.
Dr Buckberg. Today, we usually operate on the akinetic thick-
walled ventricles, and I believe that may make a difference in the
future. We found a slightly lower mortality rate, despite lower EF
and larger volumes, when we used the beating methods. This may
have impact because the normal end-systolic volume index is
approximately only 25 mL/m2. In a recent analysis, we found
10-year survival was greater than 80% if the systolic volume index
was less than 120 mL/m2. This relatively flat trajectory, which you
described and saw in group 3, may emphasize the importance of
using a patch inside the ventricle for future restoration. Do you
have any volume measurements to give us some insight about how
this affected the future of the patients in your series?
Dr Bolooki. No, I do not have volume measurements in pa-
tients in this report. We are presently trying to estimate intraop-
eratively how much or to what extent the LV volume has been
reduced. However, with the intraventricular patch, the LV shape
changes, and the angle of the echocardiography beam does not
always match the plane comparable to preoperative views. I be-
lieve that your group is performing this type of study and postop-
erative angiography. They are probably in a better position with
their prospective studies to show the relation between a decrease in
LV volume and long-term survival. No doubt if the end-systolic
volume index of the LV is small, the patient will survive longer,
according to your studies.
Dr Buckberg. We found 3 factors that may be critical to the
decision and prognosis process. They include measuring the area
of nonfunctioning muscle that is akinetic or dyskinetic and eval-
uating the function of the remote muscle and the septal muscle.
This requires that we use a left anterior oblique view, either by
ventriculogram or magnetic resonance imaging. We also measure
end-systolic ventricular volume. These preoperative measurements
may become a paradigm shift in our current analysis. What are
your thoughts about making measurements of the muscle that is
left in place to determine the impact of retained muscle on prog-
nosis?
Dr Bolooki. I think that is an excellent question. We have
known for some time that the EF of the remote areas and the basal
segments is highly predictive of early and long-term survival. This
point was emphasized by your group recently. We have not per-
formed any wall motion studies to see whether the remaining LV
segments retain the preoperative EF or show improvement after
the operation. Also, myocardial revascularization may improve the
function of the remote myocardial segments. Actually, postoper-
ative cardiac function studies were beyond the aims of the present
work. In this study, we tried to evaluate the relation of certain
preoperative factors with long-term survival and all-cause mortal-
ity as an end point.
Dr Buckberg. The mitral valve was approached in only 3% of
your patients. We have performed it in approximately 25%. Of
course, functional mitral regurgitation relates to a high ventricular
volume and may be a cause of the high PA pressures you found to
adversely affect results. This can be corrected at the time of
restoration by performing an annuloplasty and by narrowing the
increased width between the papillary muscle heads with a cir-
cumferential suture. I believe that future mitral management will
be defined by geometry and not by the grade of regurgitation. What
are your thoughts about treating the mitral valve in this disease,
and do you make this measurement preoperatively or in the oper-
ating room?
Dr Bolooki. As you indicated, only 3% of these patients
underwent mitral valve surgery. In those patients, the subvalvular
apparatus was extensively damaged, and there was severe mitral
regurgitation. I believe the technique of mitral valve repair that you
presented last year before The American Association for Thoracic
Surgery by using a limited circumferential suture is a good one. I
have tried the method also, but not in patients after volume
reduction surgery. I believe your suggestion of correcting the valve
and the LV volume simultaneously is an important one. The
combination of mitral valve incompetence and ischemic heart
disease has been a challenge for all of us, and we do not always
know the correct answer to its management. I try to decide on the
management of mitral valve preoperatively, as well as in the
operating room, on the basis of clinical and echocardiography
findings. We extensively use echocardiography in the operating
room to evaluate the valve before and after repair.
Dr Buckberg. In conclusion, your goals and management are
really similar to ours. We also deal with what we call the VVV—
the vessels, the valve, and the ventricle. These components of heart
failure cannot be separated, but they can change surgically and
may reflect the pioneering frontier Dr Doty described in his pres-
idential address.
Dr Bolooki. Thank you very much Dr Buckberg. I agree with
the VVV (ventricle, vessels, and valve) repair that you brought up,
which is one more innovation from you. I also enjoyed President
Doty’s presentation and admire his pioneering contributions to
cardiac surgery.
Dr Roger Baskett (Halifax, Nova Scotia, Canada). If you are
comparing groups of patients from very different eras over a long
period of time, an essential piece is how many patients are receiv-
ing optimal medical heart failure therapy. Specifically, who is
receiving angiotensin-converting enzyme inhibitors or -blockers,
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and how many patients in each group have automatic internal
cardioverter-defibrillators in place?
Dr Bolooki. You are correct that patients in the early 1980s did
not receive angiotensin-converting enzyme inhibitors and -block-
ers as freely as today. The optimal medical therapy of heart failure
as we know it today was used in these patients beginning in the
early 1990s and probably contributed a great deal to patient sur-
vival.
Cardioverter-defibrillators were used in approximately 10% of
the surviving patients. During the 1980s, recurrent malignant VTs
that were unresponsive to pharmacologic therapy or ablative sur-
gery were managed with the implantation of patches on the ven-
tricles according to a sudden-death protocol. We believe that the
patients in this study who had preoperative VT were managed very
effectively. In fact, the long-term survival curves in this group
were similar to patients who did not have preoperative VT.
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